Value-Based Pricing
Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.
Most Favored Nation pricing: what it means for policy, patients and pharma
5 May 2026
US pharmaceutical prices are the highest in the world – President Trump’s Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice?
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
Saudi Arabia’s healthcare system is undergoing major transformation under Vision 2030, reshaping regulation, funding and delivery models across the Kingdom. The introduction of a formal health technology assessment (HTA) framework and evolving reimbursement pathways are central to improving access to value-based healthcare.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence.
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.